Endothelial-Rac1 Is Not Required for Tumor Angiogenesis unless αvβ3-Integrin Is Absent by D'Amico, Gabriela et al.
Endothelial-Rac1 Is Not Required for Tumor
Angiogenesis unless avb3-Integrin Is Absent
Gabriela D’Amico
1*
¤, Stephen D. Robinson
1, Mitchel Germain
1, Louise E. Reynolds
1, Gareth J. Thomas
2,
George Elia
1, Garry Saunders
1, Marcus Fruttiger
3, Victor Tybulewicz
4, Georgia Mavria
5, Kairbaan M.
Hodivala-Dilke
1*
1Adhesion and Angiogenesis Laboratory, Institute of Cancer, Bart’s and The London, Queen Mary’s School of Medicine and Dentistry, London, United Kingdom, 2Centre
for Tumour Biology, Institute of Cancer, Bart’s and The London, Queen Mary’s School of Medicine and Dentistry, London, United Kingdom, 3Institute of Ophthalmology,
University College London, London, United Kingdom, 4Division of Immune Cell Biology, National Institute for Medical Research, London, United Kingdom, 5Cancer
Research UK Centre for Cell and Molecular Biology, Institute of Cancer Research, London, United Kingdom
Abstract
Endothelial cell migration is an essential aspect of tumor angiogenesis. Rac1 activity is needed for cell migration in vitro
implying a requirement for this molecule in angiogenesis in vivo. However, a precise role for Rac1 in tumor angiogenesis has
never been addressed. Here we show that depletion of endothelial Rac1 expression in adult mice, unexpectedly, has no
effect on tumor growth or tumor angiogenesis. In addition, repression of Rac1 expression does not inhibit VEGF-mediated
angiogenesis in vivo or ex vivo, nor does it affect chemotactic migratory responses to VEGF in 3-dimensions. In contrast, the
requirement for Rac1 in tumor growth and angiogenesis becomes important when endothelial b3-integrin levels are
reduced or absent: the enhanced tumor growth, tumor angiogenesis and VEGF-mediated responses in b3-null mice are all
Rac1-dependent. These data indicate that in the presence of avb3-integrin Rac1 is not required for tumor angiogenesis.
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Introduction
Tumor growth and metastasis are both dependent on the
development of a tumor vasculature in a process termed
angiogenesis. This process involves changes in the migration and
proliferation of endothelial cells to form capillaries which invade
into the growing tumor mass to supply it with nutrients and
oxygen [1]. The list of molecular co-ordinators of angiogenesis is
vast and includes some members of the family of extracellular
adhesion molecules, integrins, and several growth factors and their
receptors such as vascular endothelial growth factor (VEGF) and
VEGF-receptor2 (VEGFR2) [2]. Blood vascular endothelial cells
express several integrins including avb3, a predominant vitronec-
tin receptor. Inhibitors of avb3 have been developed as anti-
angiogenic agents for the treatment of cancer [2]. Indeed avb3-
and VEGF-inhibitors, used in combination with chemotherapy,
are both in Phase III clinical trials, the former for the treatment of
glioblastoma and the latter especially for colorectal cancer
[3,4,5,6,7]. However, neither anti-integrin nor anti-VEGF treat-
ments are effective enough at blocking angiogenesis to completely
halt cancer progression and, at best, can extend mean patient
survival by a few months [8,9,10,11]. In contrast to the inhibition
studies, global genetic ablation of b3-integrin results in viable,
fertile animals which display enhanced pathological angiogenesis
due in part to the up-regulation of VEGFR2 [12], whereas in a
transgenic model, where the cytoplasmic tail of b3-integrin is
mutated, pathological angiogenesis is impaired [13]. Taken
together these data demonstrate that the molecular mechanisms
by which these molecules regulate angiogenesis are complex and
in need of further investigation.
There are several examples where the levels of b3-integrin have
been reported to be undetectable in developing blood vessels.
Apart from the lack of b3-integrin in Glanzmann thromabastenic
patients, there are several physiological examples where b3 levels
are low or undetectable: (1) during embryonic development, b3-
integrin expression is barely detectable until mouse embryonic day
E15.5 onwards, before which, most developmental angiogenesis is
already well established [14]; (2) b3-integrin expression is not
observed in the vasculature of healing liver [15]; (3) the vasculature
of angiosarcomas has undetectable levels of b3-integrin [16]; (4)
the vasculature of lung metastases originated from colorectal
cancer also lack b3-integrin [17,18]; (5) the blood vessels in
neuroendocrine tumors also show no significant change in b3-
integrin levels between normal and tumor tissue [19]; (6) in Lewis
cell lung carcinomas, b3-integrin expression is absent until the
tumors reach a relatively large size of 500 mm
3 or more suggesting
that the initial stages of angiogenesis lack b3-integrin [15]. Taken
together, these types of data suggest that screening for b3-integrin
levels, will be important in better detecting which tumor types will
be responsive to b3-specific anti-angiogenic therapy. Indeed the
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9766lack of an anti-tumor effect of many of the anti-avb3-inhibitors,
except for in glioblastma, suggest that perhaps b3-integrin in the
vasculature of some tumors is not significantly high or functional.
Thus it is of importance to understand the molecular basis of b3-
integrin low/deficient angiogenesis.
Downstream signalling pathways of both integrins and growth
factor receptors involve RhoA, Cdc42 and Rac1, all members of
the family of Rho GTPases. RhoA, Cdc42 and Rac1 can be
activated when GTP-bound, and inactivated, when GDP-bound.
The activation of RhoA has been reported to be involved in the
development of actin stress fibres, Cdc42 in filopodia formation
and Rac1 in membrane-ruffling [20]. Rac1 has been shown to be
required for the migration of cells, including endothelial cells, and
also it appears to play a role in vascular tube formation and lumen
formation, at least in vitro [21,22]. Its involvement in the function
of endothelial cells has also been illustrated by the activation of
Rac1 under flow and shear stress [23]. Recently, some studies have
suggested a role for Rac1 in endothelial cells in vivo. For example,
haploinsufficiency of Rac1 in Tie2-Cre mice results in the poor
regulation of blood pressure, vasodilation and impaired hind limb
ischemia-induced neovascularization, suggesting that a 50% loss of
Rac1 in Tie2-Cre mice is sufficient to affect this process [24]. In
addition, Rac1-deletion in Tie2-Cre mice has implied a role for
Rac1 in developmental vasculogenesis, due, possibly, to its deletion
both in Tie2-positive endothelial cells and in approximately 80%
of hematopoetic cells which are also Tie2-positive [25]. However,
since these embryos die at E9.5, before developmental angiogen-
esis can proceed fully, the precise effect of endothelial-Rac1-
deficiency in tumor angiogenesis in vivo is unknown.
Here we show that, surprisingly, the inducible-deletion of Rac1
in adult endothelial cells does not affect tumor angiogenesis or
VEGF-mediated angiogenesis in adult mice. However, in the
absence of b3-integrin, the dependency of these processes on Rac1
becomes apparent. Our data indicate that Rac1, in adult
endothelial cells, is not normally required for the migration and
capillary formation necessary in adult neovascularization in vivo
and that the role for this Rho GTPase in vivo may well be different
to its functions in vitro.
Results
Tumor growth and tumor angiogenesis in b3-null, but
not wild-type mice, are dependent on adult endothelial
Rac1 expression
Endothelial cell migration is a critical feature of tumor
angiogenesis and is thought to involve both changes in integrin
expression and the activity of Rho GTPases such as Rac1 [26].
However, a precise role for Rac1 in tumor angiogenesis has never
been addressed. We provide evidence that Rac1 activity (Rac1-
GTP) is elevated in b3-integrin knockout endothelial cells without
affecting total Rac1 levels, and that transduction of human b3-
integrin into b3-null endothelial cells is sufficient to reduce Rac1-
GTP levels back to wild-type levels (Figure 1A, B). Given the
enhanced pathological angiogenic responses in b3-null mice [12]
we asked whether endothelial Rac1 was differentially required in
tumor angiogenesis in adult wild-type or b3-null mice.
To investigate whether Rac1-deficiency in endothelial cells
affected tumor growth and tumor-associated angiogenesis in adult
Figure 1. Increased active levels of Rac1 in b3-integrin-deficient endothelial cells. A. Active levels of Rac1 were examined by GST-PAK pull-
downs. Western blot analysis of active Rac1 bound to GST-PAK (Rac1-GTP) and total Rac1 from wild-type, b3-integrin null, and b3-null primary lung
endothelial cells transduced with human b3-integrin (rescue). Immunoblots were quantified by densitometry, and the levels of GTP-bound Rac1
normalised to total Rac1 levels. Active levels of Rac1 were increased approximately 3 fold in b3-null endothelial cells when compared with wild-type
controls (*P,0.01), however, total levels of Rac1 were expressed equally in both genotypes. Furthermore, active levels of Rac1 were reduced to wild-
type levels in rescue cells (*P,0.01). Results shown are the means + s.e.m of 3-4 independent experiments. B. Flow-cytometric analysis shows that
surface levels of b3-integrin were not detectable in b3-null (dashed line) cells when compared with wild-types (bold line) endothelial cells (left panel).
Rescue cells expressed b3-integrin (bold line, right panel). Grey peaks represent isotope IgG controls. Bar graph shows means + s.e.m of relative
surface b3-integrin expression in wild-type (white), b3-null (black) and rescue (grey) endothelial cells compared with negative control (*P,0.001,
N=3 independent experiments).
doi:10.1371/journal.pone.0009766.g001
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RNA interference (RNAi) was employed (pSico-Rac1). This vector
allows tissue-specific activation of Rac1 short hairpin RNA
(shRNA) in Cre-expressing cells in vivo. As a positive control (for
inhibiting angiogenesis), pSico-Flk-1 was employed for the
depletion of Flk-1 (VEGFR2). As a negative control pSico-Con,
targeting firefly luciferase was also used.
The efficiency of the system was first tested in vitro. The pSico
plasmid contains a GFP-reporter that is excised after Cre-
mediated recombination and shRNA expression. Wild-type
primary endothelial cells infected with pSico-Rac1 lentiviruses
were analyzed for GFP-expression and showed high-efficiency
transduction. GFP-positive cells were then isolated by FACS and
transfected with a Cre expression-plasmid (pTURBO-Cre). Near
complete recombination, with a subsequent loss of GFP
expression, was observed for all transduced cells (P,0.01,
Figure 2A). Moreover, a significant reduction of both Rac1 and
Flk-1 mRNA and protein levels was achieved in pSico-Rac1 or
pSico-Flk-1 transduced cells, respectively. As expected, no
significant changes in either mRNA or protein levels of Rac1 or
Flk-1 were observed in pSico-Con infected cells (Figure 2B).
To study the effect of pSico-Rac1 on tumor growth, wild-type/
Tie1-Cre
+ and b3-null/Tie1-Cre
+ mice were injected subcutane-
ously with murine B16F0 melanoma cells and pSico-Con, pSico-
Rac1 or pSico-Flk-1 lentiviral suspensions injected intratumorally
on days 5 and 10 after tumor cell inoculation. In line with our
previous findings [12,27], tumor size in pSico-Con treated b3-
null/Tie1-Cre
+ mice was greater than similarly treated wild-type/
Tie1-Cre
+ mice. Results also showed that although pSico-Flk-1
treatment reduced significantly B16F0 melanoma size (P,0.05) in
both genotypes, when compared with pSico-Con controls, pSico-
Rac1-treatment did not affect tumor size in wild-type/Tie1-Cre
+
mice, but significantly reduced tumor size in b3-null/Tie1-Cre
+
mice (Figure 3A).
To determine the efficacy of the lentiviruses in vivo, double-
immunostaining for PECAM-1 and GFP was performed in
sections of tumors grown in wild-type/Tie1-Cre
2 or wild-type/
Tie1-Cre
+ mice treated with either pSico-Rac1 or pSico-Flk-1
Figure 2. Cre-regulated depletion of Rac1. A. Wild-type primary endothelial cells were infected with pSico-Rac1 lentivirus. High-efficiency
transduction was achieved as indicated by uniform GFP expression in infected cells (left panel). Cells sorted for GFP positivity and transfected witha
Cre-recombinase expression plasmid (pTURBO-Cre) showed a significant loss of GFP (right panel). Scale bar: 10 mm. B. One week after pTURBO-Cre
transfection, levels of mRNA, detected by semi-quantitative RT-PCR (upper panels), and protein, detected by Western blotting (lower panels), showed
successful Rac1- and Flk-1-depletion in pSico-Rac1 and pSico-Flk-1 infected cells, respectively. Actin RT-PCR and Western blotting for Hsc-70 were
carried out to ensure equal RNA and protein loading, respectively. Bar graphs represent densitometric readouts of mRNA of relative Actin or Hsc-70
protein levels, respectively. *P,0.01. N=3 independent experiments.
doi:10.1371/journal.pone.0009766.g002
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vessels under both conditions. In wild-type/Tie1-Cre
2 mice,
GFP expression was detected in both the tumor cells and the
majority of endothelial cells lining blood vessels, indicating a high
efficiency of lentiviral infection in vivo. In contrast, analysis of
tumors grown in wild-type/Tie1-Cre
+ mice showed a loss of GFP
expression in endothelial cells but not tumor cells, indicating that
endothelial-specific Cre-recombination was efficient (Figure 3B).
Taken together, these data indicate that, while no biological effect
of Rac-1 knockdown was observed in wild-type/Tie1-Cre
+, the
lentivirus treatment efficiently reduced expression of Rac1 in
tumor blood vessels from these animals.
To examine the effect of endothelial Rac1-depletion on tumor
angiogenesis, blood vessel density was quantified by counting the
numbers of PECAM-1
+/GFP
2 blood vessels per unit area across
entire midline tumor sections from size-matched tumors of wild-
type/Tie1-Cre
+ and b3-null/Tie1-Cre
+ mice treated with either
pSico-Con, pSico-Rac1 or pSico-Flk-1 lentiviruses. Once again,
concurrent with our previous work [12,27], blood vessel density in
pSico-Con treated b3-null/Tie1-Cre
+ mice was significantly
greater than in pSico-Con treated wild-type/Tie1-Cre
+ mice.
However, although pSico-Flk-1 treatment inhibited significantly
tumor angiogenesis in both wild-type/Tie1-Cre
+ and b3-null/
Tie1-Cre
+ mice (P,0.05), pSico-Rac1-treatment did not affect
tumor angiogenesis in wild-type/Tie1-Cre
+ but did inhibit tumor
angiogenesis significantly in b3-null/Tie1-Cre
+ mice (Figure 3B).
These results indicate that Rac1-depletion in tumor endothelial
cells does not affect tumor growth or tumor angiogenesis in wild-
type/Tie1-Cre
+ mice but does inhibit both these processes in b3-
null/Tie1-Cre
+ mice.
Further confirmation of the role of endothelial Rac1 in tumor
growth and angiogenesis was accomplished by using a genetic
ablation approach that allows conditional Rac1-deletion in an
inducible-manner. Rac1-floxed mice [28] were crossed with
PDGFB-iCreER transgenic mice (23) (where Cre expression, in
adult animals, is restricted primarily to angiogenic/proliferating
endothelial cells [29]) to generate tamoxifen-inducible endothelial-
specific Rac1-deficient mice (Rac1 flox/flox PDGFB-iCreER). To
verify that tamoxifen treatment of Rac1 flox/flox PDGFB-iCreER
endothelial cells induced Rac1-deletion, endothelial cells and non-
endothelial cells were isolated from Rac1 flox/flox PDGFB-
iCreER mice and treated with tamoxifen (OHT) or ethanol
(vehicle) in culture. Rac1 protein levels were barely detected in
Rac1 flox/flox PDGFB-iCreER tamoxifen-treated endothelial
cells when compared with vehicle-alone treated Rac1 flox/flox
PDGFB-iCreER or tamoxifen-treated Rac1 flox/flox (PDGFB-
iCreER negative) controls. Importantly, tamoxifen treatment of
non-endothelial cells isolated from Rac1 flox/flox PDGFB-
iCreER mice had no effect on Rac1 expression (Figure 4A).
Rac1 flox/flox PDGFB-iCreER mice were injected subcutane-
ously with B16F0 cells and, one day later, treated with tamoxifen
(OHT) or placebo administered by slow-release pellets implanted
subcutaneously to induce Cre-activity in PDGFB-positive cells.
Deletion of Rac1 in the vascular endothelium did not affect tumor
size or tumor angiogenesis when compared with controls
(Figure 4B).
As yet an additional test of the roles played by Rac1 and b3-
integrin in angiogenesis in vivo, Rac1 flox/flox PDGFB-iCreER
animals received tamoxifen pellet implants. These animals then
were injected subcutaneously with B16F0 cells and subsequently
received intra-tumoral injections of pSico-Con (as described
above) or a pSico lentivirus directed against b3-integrin (pSico-
b3). Tumors treated with pSico-Con grew to an expected size of
approximately 800 mm
3. pSico-b3 treated tumors, however, were
significantly smaller (P,0.05, Figure 4C). Blood vessel counts of
endomucin stained tumor sections showed a significant reduction
in angiogenesis after treatment with pSico2b3( P,0.001,
Figure 4C). Taken together, data from Rac1 flox/flox PDGFB-
iCreER animals provided a second line of evidence that tumor
growth and angiogenesis in vivo does not normally depend on
Rac1.
Already published studies suggest that Rac1 plays a role in
vascular tube formation, at least in vitro [21,22]. As such, the data
describe here were somewhat surprising. To further test the effect
of Rac1 deletion in another neovascularization assay, the influence
of Rac1 deletion was analyzed in the post-natal developing retina
[29]. Wild-type PDGFB-iCreER and Rac1 flox/flox PDGFB-
iCreER newborn pups were treated daily with tamoxifen by oral
gavage and their retinas were examined at P12. No significant
differences in central primary plexus, or peripheral primary plexus
branch points were observed between the two genotypes
(Figure 5). Therefore, deficiency of Rac1 in endothelial cells is
not sufficient to alter neovasculatization in vivo, at least when b3-
integrin is present.
Using multiple in vivo approaches, we demonstrated that
endothelial Rac1 is not essential for tumor growth or tumor
angiogenesis in adult wild-type mice, but that these processes
become Rac1-dependent in the absence of b3-integrin.
Rac1 is not required for VEGF-mediated angiogenesis in
wild-type mice but is in b3-null mice
Given that VEGF is a key positive regulator of pathological
angiogenesis and that VEGF/VEGFR2 signalling is known to
activate Rac1 in vitro, we tested the effect of endothelial-specific
Rac1-depletion on VEGF-mediated neovascularization in vivo.
Synthetic sponges were implanted subcutaneously into wild-type/
Tie1-Cre
+ and b3-null/Tie1-Cre
+ mice and injected in situ with
Figure 3. Endothelial-specific Rac1-depletion does not impair tumor growth wild-type mice but does in b3-null mice. A. Murine B16F0
cells (10
6) were injected subcutaneously into the flanks of wild-type/Tie1-Cre
+ or b3-null/Tie1-Cre
+ mice. Lentiviral vector suspensions (10
6 i.u/ml) of
pSico-Con, pSico-Rac1 and pSico-Flk-1 were injected intratumorally on days 5 and 10 after tumor cell injection. Representative macroscopic
appearance of 14-day-old B16F0 pSico-Con-, pSico-Rac1- and pSico-Flk-1- treated melanomas in both genotypes. Scale bar: 5 mm. Bar graph shows
mean tumor volume per mm
3 (+ s.e.m.). Tumor size was reduced significantly in pSico-Flk-1-treated mice of both genotypes (*P,0.05) and in pSico-
Rac1 treated b3-null/Tie1-Cre
+ but not in pSico-Rac1-treated wild-type/Tie1-Cre
+ mice (n.s.d, no significant differences). N=4–6 animals per condition.
B. Representative merged images of PECAM-1 (red) and GFP (green) -immunostained sections from pSico-Rac1-treated B16F0 tumors grown in wild-
type, wild-type/Tie1-Cre
+, b3-null and b3-null/Tie1-Cre
+ mice. PECAM-1-positive staining identified endothelium. GFP-positive staining was observed
in tumor cells (concave arrowheads) and in PECAM+ endothelium (arrows) of blood vessels in B16F0 tumors from wild-type and b3-null control mice,
indicating successful pSico-Rac1 lentivirus infection in vivo. Loss of GFP detection in most PECAM-1-positive microvessels (small arrowheads), but not
in B16F0 tumor cells, was observed in pSico-treated tumors grown in wild-type/Tie1-Cre
+ and b3-null/Tie1-Cre
+ mice, indicating successful
endothelial-specific Cre recombination in vivo. Scale bar: 10 mm. Bar graph shows mean numbers of PECAM-1
+/GFP
2 vessels per unit area of tumor
section per mm
2 (+ s.e.m). Blood vessel density was reduced significantly in pSico-Flk-1-treated mice of both wild-type/Tie1-Cre
+ and b3-null/Tie1-
Cre
+ mice (*P,0.05) and in pSico-Rac1-treated b3-null/Tie1-Cre
+ mice but not pSico-Rac1-treated wild-type/Tie1-Cre
+ mice (n.s.d, no significant
differences). N=4 animals per condition.
doi:10.1371/journal.pone.0009766.g003
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PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9766Figure 4. Genetic ablation of Rac1 in endothelial cells does not impair tumor growth or tumor angiogenesis. A. Western blot analysis
of Rac1 flox/flox PDGFB-iCreER OHT-treated primary endothelial cell extracts showed that Rac1 was barely detectable (lane 3) when compared with
Rac1 flox/flox OHT-treated (lane 1) or Rac1 flox/flox PDGFB-iCreER vehicle treated (lane 2) endothelial cell extracts (left panel). Western blots of
extracts from non-endothelial cells, treated as described above, showed no differences in Rac1 expression (right panel). Hsc-70 provided loading
controls. Bar graphs represent densitometric values relative to Hsc-70. N=2 independent experiments. B. B16F0 tumor volume and angiogenesis
(blood vessel density) from tumors grown in OHT-treated Rac1 flox/flox (1, white), or placebo- (2, grey) or OHT- (3, black) treated Rac1 flox/flox
PDGFB-iCreER mice. Left bar graph shows mean tumor volume in mm
3 (+ s.e.m) for 10-day-old tumors. No significant differences in tumor size were
observed between groups. N=6–7 animals per group. Right bar graph shows mean number of PECAM-1 positive vessels per tumor area per mm
2 (+
s.e.m.) for 10-day-old tumors. No significant differences in microvessel density were observed between groups. N=4 animals per group. C. B16F0
tumor volume and angiogenesis (blood vessel density) from tumors grown in OHT-treated Rac1 flox/flox PDGFB-iCreER animals. Tumors were
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pSico-Rac1 or pSico-Flk-1 lentiviral suspensions. After 15-days,
angiogenic responses were assayed histologically. Results showed
that, as expected, VEGF-mediated neovascularization was elevat-
ed in b3-null/Tie1-Cre
+ pSico-Con treated mice when compared
with similarly treated wild-type/Tie1-Cre
+ controls. pSico-Flk-1
treatment inhibited significantly VEGF-induced angiogenesis in
both genotypes. However, pSico-Rac1 treatment had no effect in
wild-type/Tie1-Cre
+ mice, but did inhibit neovascularization in
b3-null/Tie1-Cre
+ mice when compared with pSico-Con controls
(Figure 6A). Additionally, using a second approach, VEGF-
induced angiogenesis in scrambled control-siRNA (Con siRNA)
injected sponges in b3-null mice was elevated when compared
with Con siRNA treated sponges in wild-type mice, and Rac1-
specific-siRNA injection into sponges inhibited significantly
angiogenic responses in b3-null, but not wild-type, mice
(Figure 6B). Taken together these data suggest that Rac1
expression in endothelial cells is not essential for VEGF-mediated
angiogenesis in wild-type mice but is involved in such responses in
b3-null mice in vivo.
Further analysis of the role of Rac1 in VEGF-induced
neovascularization responses was carried out using ex vivo aortic
ring assays. Thoracic aortic rings from wild-type and b3-null mice
were transfected with either a scrambled control (Con) or Rac1-
specific siRNA. Rac1 mRNA and protein levels were reduced in
aortic rings from both genotypes by approximately 85% after
transfection with Rac1-specific siRNA (Figure 6C). These rings
were embedded in Matrigel in the presence of VEGF alone or
VEGF plus DC101, an antibody that blocks Flk-1 activity [27].
Quantitation of microvessel outgrowth showed that Rac1-
depletion did not alter wild-type microvessel sprouting, but
inhibited significantly the enhanced numbers of microvessel
sprouts from b3-null aortas (Figure 6D). In addition, DC101
treatment significantly affected this process in Con- and Rac1-
siRNA transfected aortic rings from both genotypes (P,0.01,
Figure 6D).
Rac1-depletion does not affect the levels or activity of
other tested Rho GTPases in either wild-type or b3-null
endothelial cells
To begin to understand the mechanisms responsible for the
biological effects of Rac1-depletion in wild-type and b3-null
endothelial cells, we examined first the levels and activity of Rac2,
Rac3, Cdc42 and Rho. Rac1-specific siRNA treatment of
microvascular endothelial cells isolated from wild-type or b3-null
mice reduced significantly Rac1 mRNA levels (Figure 7A), total
protein levels (Figure 7B), and active Rac1 levels (Figure 1A). In
contrast, transfection of endothelial cells using Con siRNA had no
effect on Rac1 expression in either genotype. Importantly, no
compensation by expression or activity of other tested Rho-related
GTPases (Rac2, Rac3, Cdc42 and RhoA) were observed in either
wild-type- or b3-null-Rac1-depleted endothelial cells (Figure 7B).
These results suggest that the lack of an inhibitory response to
Rac1 loss in wild-type endothelial cells is not due to compensation
by either Rac2, Rac3, Cdc42 or RhoA. In addition, the
dependency of b3-null endothelial cells on Rac1 is not due to
any intrinsic change in these Rho GTPases.
Rac1 is not essential for VEGF-mediated endothelial cell
proliferation, scratch closure or tube formation in 2-
dimensions
Given that Rac1 has been implicated in regulating positively cell
migration, proliferation and tube formation, at least in vitro,w e
decided to examine also whether Rac1-depletion in b3-null
endothelial cells affects these processes.
Analysis of endothelial cell growth by seeding equal numbers of
Mock, Con- or Rac1-siRNA transfected wild-type or b3-null
endothelial cells and counting the total number of cells per
condition between 0 and 3 days showed no significant differences
between Rac1-depleted and control cells in either genotype despite
the increased growth rates of b3-null endothelial cells (Figure 8A).
In addition, Trypan blue exclusion showed that the percentage of
cells that were viable did not change after Rac1-depletion between
1-3 days after seeding in either genotype (Figure 8B). These data
suggest that Rac1-knockdown does not inhibit the proliferation or
viability of wild-type or b3-null endothelial cells in culture. In
contrast, Rac1-depletion inhibited VEGF-mediated 2-dimensional
(2D) scratch closure (Figure 8C) and cord formation (Figure 8D)
when compared with Mock and Con siRNA controls without
affecting cell viability (Figure 8D). These results confirm the
reported role of Rac1 in promoting VEGF-mediated endothelial
cell migration and cord formation conducted in standard 2D tissue
culture conditions. However, given that the requirement for Rac1
in 3-dimensional (3D) versus 2D migration may be different
[30,31], and that our in vivo data did not show a requirement for
Rac1 in wild-type angiogenesis, the effect of Rac1-depletion in
endothelial cell migration was examined further in a 3D-modified
Boyden chamber assay. Importantly, knockdown of Rac1 had no
effect on VEGF-induced 3D chemotactic migration of wild-type
injected at days 5 and 10 (after initial inoculation) with pSico-Con (1, white) or pSico- b3 (2, black) and harvested at day 14. Left bar graph shows
mean tumor volume in mm
3 (+ s.e.m). P,0.05. N=5 animals per group. Right bar graph shows mean number of endomucin positive vessels per
tumor area per mm
2 (+ s.e.m.). P,0.001. N=5 animals per group.
doi:10.1371/journal.pone.0009766.g004
Figure 5. Postanatal retinal vascularization is not affected by
endothelial Rac1 deletion. Wild-type PDGFB-iCreER and PDGFB-
iCreER; Rac1 flox/flox newborn pups were treated daily with tamoxifen
and their retinas were examined at P12. The vasculature was visualised
by Interleukin b4 staining (ILB4 - green) and Claudin 5 (red). No obvious
differences in vascularization were observed between genotypes. Scale
bar: 10 mm upper micrographs; 100 mm lower micrographs.
doi:10.1371/journal.pone.0009766.g005
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endothelial cells. As controls wild-type endothelial cells transfected
with Con siRNA and treated with DC101 showed baseline
migration and this was further inhibited in similarly treated b3-
null cells (P,0.05, Figure 8E). These results suggest that the role
of Rac1 in 3D and 2D is different.
Rac1 depletion does not affect VEGF-receptor2
expression
Since we have shown previously that the loss of b3-integrin can
elevate VEGF-mediated responses, VEGFR2/Flk-1 levels and Flk-
1 activity [12,27] we sought to determine the effect of Rac1-
depletion on Flk-1 levels in wild-type and b3-null endothelial cells.
Expression of Flk-1 was analyzed in primary wild-type and b3-null
endothelial cells after transfection with either scrambled-control or
Rac1-specific siRNA. Western blot analysis recapitulated our
previous work showing that b3-null endothelial cells express higher
levels of Flk-1 than wild-type controls. However, Rac1-depletion
did not affect Flk-1 levels in either genotype (Figure 9A). This
suggested that the elevated Rac1 activity that occurs in b3-null
endothelial cells is downstream of changes in VEGFR2.
Although Rac1 appears dispensable to normal in vivo angiogen-
esis, the question remained as to whether elevated Rac1-activity
could influence angiogenesis. To test whether elevated Rac1-
activity influences 3D tube formation in vitro, both WT Rac1 and
constitutively active Rac1 (Rac1 QL) were over-expressed in
human umbilical endothelial cells (HUVEC) plated on a confluent
layer of fibroblasts [32]. Tubules were visualized by PECAM-1
staining after 5 days in culture. The number of branch points in
HUVEC overexpressing either form of Rac1 was significantly
higher when compared to vector only transfected controls
(P,0.02, Figure 9B), demonstrating that elevated Rac1 levels
or activity can enhance tube formation.
Overall, our findings suggest that normally (in adult wild-type
mice) angiogenesis does not depend on Rac1. However, when b3-
integrin levels are altered, tumor growth, tumor angiogenesis and
VEGF-driven angiogenesis are enhanced and dependent on Rac1.
Discussion
Here we describe the role of Rac1 in tumor growth, tumor
angiogenesis and VEGF-induced angiogenesis in vivo. Importantly,
none of these processes were affected when Rac1 was depleted or
deleted in the tumor endothelium of adult wild-type mice. These
findings reveal that, unexpectedly, Rac1 expression in adult
endothelial cells is not essential for tumor angiogenesis. However,
we report that active levels of Rac1 are increased in b3-null
endothelial cells and that the enhanced tumor growth, tumor
angiogenesis and VEGF-mediated responses in b3-null mice were
all dependent on endothelial Rac1 expression since Rac1-
depletion in b3-null endothelial cells reduced significantly these
responses. These data demonstrate that the requirement for
endothelial-Rac1 becomes important when vascular b3-integrin is
absent.
Endothelial cell proliferation, migration and tube formation are
essential processes during tumor angiogenesis and Rac1 activity is
believed to be important for these cellular processes in vitro
implying a possible requirement for this molecule in angiogenesis
in vivo. However our data demonstrating that tumor angiogenesis
and VEGF-induced angiogenesis in vivo were not affected in either
pSico-Rac1-infected wild-type/Tie1-Cre
+ mice or tamoxifen-
treated Rac1 flox/flox PDGFB-iCreER mice, imply that angio-
genic processes such as proliferation, migration and tube
formation in vivo are not affected by the induced-loss of Rac1 in
adult endothelial cells. In contrast, recent studies have suggested a
positive role for Rac1 in endothelial cell function. For example, a
50% loss of Rac1 in Tie2-Cre mice results in reduced
neovascularization in the hind-limb ischemia model [24]. In
addition, Rac1-deletion in Tie2-Cre embryos results in early
lethality due to severe heart and vasculogenic defects by E8.5 [25].
The apparent discrepancies between our results and those
reported in Tie2-Cre mice may be due to several reasons. For
example, the haploinsufficiency or deletion of Rac1 in these
systems is from early embryogenesis and this has been shown to
induce changes in blood pressure and vasodilation [24] that, in
turn, are known to affect neovascularization indirectly [33] and
therefore it is likely that such changes in blood pressure would
actually affect angiogenesis in the Rac1-haploinsufficient-Tie2-Cre
mice. In contrast, using the pSico or PDGFB-iCreER-inducible
systems we have deleted Rac1, predominantly, in adult tumor or
VEGF-induced neo-endothelial cells themselves, thus reducing
any side effects on the whole vasculature. In addition, Cre activity
in Tie2-Cre mice, as well as being present in endothelial cells, is
also apparent in approximately 80% of hematopoietic cells
[34,35], and it is tempting to speculate that the haploinsufficiency
or deletion of Rac1 in this compartment may well affect
angiogenesis. In contrast, in the pSico models that we have used,
it is unlikely that the hematopoietic compartment is subject to
Rac1-deletion and thus these cells are unlikely to affect
angiogenesis in our system.
Regarding proliferation, our results corroborate the findings
that increased Rac1 activity correlates with enhanced endothelial
proliferation, since the elevated Rac1-activity in b3-null endothe-
lial cells show elevated proliferative capacity [36]. However, our
Figure 6. VEGF-mediated angiogenesis is dependent on endothelial-Rac1 expression in b3-null mice but not wild-type mice. A.
Representative images of 14-day-old VEGF-impregnated sponges in wild-type/Tie1-Cre
+ and b3-null/Tie1-Cre
+ mice after treatment with pSico-Con,
pSico-Rac1 and pSico-Flk-1. Endomucin-positive staining (blue) identified microvessels. Scale bar: 50 mm. Bar graph represents mean number of
microvessels per area of sponge (+ s.e.m.). Blood vessel density was reduced significantly in pSico-Flk-1-treated mice of both genotypes (*P,0.05),
and in pSico-Rac1-treated b3-null/Tie1-Cre
+ mice, but not pSico-Rac1-treated wild-type/Tie1-Cre
+ mice (n.s.d, no significant differences). N=6
sponges per group. B. Subcutaneous sponges implanted into wild-type mice were injected with either PBS or VEGF in the presence (Rac1 siRNA) or
absence (Con siRNA) of Rac1-specific siRNA. Bar graph shows mean number of laminin-positive vessels per area of sponge per mm
2 (+ s.e.m). Blood
vessel density was increased significantly in VEGF alone-treated (*P,0.01) when compared with PBS controls. Rac1 siRNA-treatment had no
significant effect (n.s.d, no significant differences). N=6–10 sponges per group. C. Semi-quantitative RT-PCR (left) and Western blot (right) analyzes
from wild-type and b3-null aortic explants transfected with either Con or Rac1 specific-siRNA. Rac1 siRNA reduced significantly the expression of both
Rac1 mRNA (*P,0.01) and protein (*P,0.001) levels. RT-PCR for Actin and Western blotting for Hsc-70 provided mRNA and protein loading controls,
respectively. Bar graphs represent mean Rac1 mRNA and Rac1 protein levels (+ s.e.m.). N=3 independent experiments. D. Ex vivo mouse aortic ring
assays. Representative high-power light micrographs of VEGF-mediated microvessel sprouting from wild-type and b3-null mouse aortic rings treated
with Con or Rac1-specific siRNA and Con siRNA plus DC101. Bar graphs represent quantification of microvessel numbers from 5-day-old VEGF-
stimulated aortic ring cultures transfected with Mock, Con or Rac1 siRNA in the presence or absence of DC101. Sprouting angiogenesis was reduced
significantly after DC101 treatment of aortas and in Rac1-specific siRNA transfected b3-null, but not wild-type, aortas. Bar graph represents mean
number microvessel sprouts/aortic ring (+ s.e.m.).*P,0.01; n.s.d, no significant differences. N=3-5 independent experiments.
doi:10.1371/journal.pone.0009766.g006
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sufficient to control microvascular-endothelial cell growth in
culture and this is in line with other data where deletion of
Rac1 does not affect cell proliferation [37].
Our data also illustrate that the requirement for Rac1 in 3D
versus 2D endothelial cell migration is different. Indeed, by
examining VEGF-induced endothelial cell migration in 2D
(scratch wound healing assays) and in 3D (3D modified Boyden
Figure 7. Rac1-depletion in endothelial cells does not affect the expression and activity of other Rho-related GTPases. A. Analysis of
mRNA expression of Rac isoforms by RT-PCR. RNA was extracted from wild-type and b3-null endothelial cells transfected with Con or Rac1 siRNA. As
expected, mRNA expression of Rac1 was significantly reduced in Rac1-depleted cells of both genotypes (*P,0.001). Rac2 and Rac3 isoforms were not
detected in either Con- or Rac1-siRNA transfected endothelial cells. Extracts of lung (lu), spleen (sp) and brain (br) act as positive controls for Rac1,
Rac2 and Rac3, respectively. Actin mRNA provided the internal control. L: ladder. Bar graphs represent relative mRNA levels of Rac1 after Mock-
(white), Con- (grey) and Rac1-siRNA (black) treatment in both genotypes. B. Western blot analyses show that Rac1 expression, as expected, was
significantly reduced in Rac1-depleted cells of both genotypes (*P,0.01). In contrast, Cdc42 and RhoA protein expression was not significantly
affected in endothelial cells after Rac1-siRNA in both genotypes. In addition, for both wild-type and b3-null endothelial cells active levels of Rac1,
Cdc42 and RhoA were examined using GST-PAK pull-down (Rac1 and Cdc42) and G-LISAH (RhoA) assays on Mock (white), Con- (grey) and Rac1-siRNA
(black) transfected cells. Bars graphs show mean relative protein (top) and active (bottom) levels (+ s.e.m.) of Rac1, Cdc42, and RhoA in Mock (white),
Con- (grey) and Rac1-siRNA (black) treated wild-type and b3-null cells. N=3 independent experiments.
doi:10.1371/journal.pone.0009766.g007
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in 2D; whereas they migrated as well as controls in 3D. Several
studies have shown that VEGF-mediated endothelial cell migra-
tion in 2D involves activation of Rac1 [38,39,40] and our data are
in line with these observations. Importantly, however, our findings
demonstrate that the involvement of Rac1 in 3D endothelial cell
migration is not as critical as originally thought and this is likely to
reflect the reason for the normal tumor angiogenesis in Rac1-
depleted mice in vivo.
The reduced VEGF-induced 2D tube formation, after Rac1-
depletion in endothelial cells, that we observed is also in line with
several reports [41,42,43,44,45,46,47]. In contrast, using a novel
3D model involving co-culture with VEGF-A-overexpresing
fibroblasts, others have shown that dominant-negative N17Rac1
has no effect on VEGF-induced capillary-like network formation
of endothelial cells [48]. These investigators showed that a
dominant negative mutant of N-Ras (a small GTPase from a
different family to that of Rac1) suppressed capillary-network
formation of endothelial cells induced by VEGF-A-producing
fibroblasts whereas the mutants of Rac1, RhoA or Cdc42 did not.
Our observations also support the notion that, in 3D environ-
ments, Rac1 is dispensable for VEGF-mediated capillary-
formation in wild-type but not b3-null aortic rings and
angiogenesis in vivo.
Previous studies have suggested that b3-integrin activation
induces Rac1 activity. For example, inhibition of endothelial cell
cyclooxygenase-2, by nonsteroidal anti-inflammatory drugs,
suppresses avb3-dependent activation of Rac1 [49,50]. Given
such crosstalk between integrins and Rac1, it is surprising that
Rac1-activity is enhanced in b3-null endothelial cells. The
increased active levels of Rac1 may reflect a compensatory
response due to the deletion of b3-integrin, since rescuing the
expression of b3-integrin in b3-null endothelial cells diminished
the activity of Rac1 to levels similar as those seen in wild-type.
Importantly, however, the expression and activity levels of other
tested Rho-related GTPases (e.g. Rac2, Rac3, Cdc42 and RhoA)
were equal in wild-type and b3-null endothelial cells suggesting
that these Rho GTPases are unlikely to compensate for the loss of
b3-integrin.
Although recent work has shown that molecules such as RhoG
can compensate for Rac-1 [51] there is also evidence that this
depends on specific signaling cascades and is not always the case
[52]. Our data suggest that this is unlikely in b3-null endothelial
cells, since we have shown, that by inhibiting Rac1 expression
alone, we can reduce the enhanced angiogenic responses of b3-
null mice back to levels observed in wild-type mice either with or
without depletion of Rac1. Although it is tempting to speculate
that RhoG activity may compensate for Rac1 in wild-type
endothelial cells, thus explaining the reduced requirement for
Rac1 in wild-type angiogenic events in vivo, this is also not likely
because Rac1-deletion in both b3-null and wildtypes brings tumor
growth and blood vessel density to the same level in both
genotypes. Thus the most logical assumption is simply that Rac1 is
not involved in tumor angioegenesis in vivo unless b3-integrin is
absent.
Our data indicate that the importance of Rac1 in angiogenic
processes is revealed only after b3-integrin is absent. We show that
the enhanced Rac1 activity in b3-null endothelial cells is
responsible, at least in part, for the elevated tumor angiogenesis
and VEGF-mediated angiogenic responses in b3-null mice.
Despite the fact that b3-null endothelial cells have elevated
VEGFR2 (Flk-1) levels [12,27,53], even after Rac1-depletion,
indicates that elevated VEGFR2 levels alone are not sufficient to
enhance angiogenesis. We show that VEGF/VEGFR2-mediated
responses are Rac1-dependent in the absence, but not in the
presence of b3-integrin, raising the possibility that downstream
signalling of VEGFR2 can either involve Rac1 or not, but that this
depends on b3-integrin.
In b3-null mice the increased Rac1-1 activity likely results in
changes in downstream signaling that confer the enhanced
angiogenic responses. For example, p38 MAP kinase signaling is
known to be downstream of Rac1 and b3-integrin and plays a role
in angiogenic processes such as endothelial cell migration and
regulation of cell-cell adhesion [54,55,56]. Thus, in future
experiments it would be of interest to examine the role of p38
MAP-kinase signaling in b3-null endothelial cells.
Several studies have shown that the blockade of avb3u s i n g
monoclonal antibodies or antagonist peptides can inhibit tumor
growth and tumor angiogenesis in mouse xenografts models and
other preclinical tests [57] and some of these agents, such as the
humanized monoclonal antibody Vitaxin [5] and the cyclic
RGD peptide Cilengitide [3,4,6,7] are in clinical trials for the
anti-angiogenic treatment of cancer. However, to date, there is
very little evidence showing these inhibitors can in fact suppress
tumor angiogenesis in humans [3,4,6,9,10,11]. This may simply
reflect that tumor angiogenesis is not actually dependent on the
activity of avb3-integrin in endothelial cells in several tumor
types. Indeed, in some human tumors, such as angiosarcomas,
Figure 8. Effect of Rac1-depletion in wild-type and b3-null cells in 2D versus 3D. A. Endothelial cell growth over 3 days was assessed by
counting the total number of Mock, Con- or Rac1-siRNA transfected wild-type and b3-null endothelial cells. Although b3-null cells grew faster than
wild-type, Rac1-depletion did not affect cell growth in either genotype. Symbols (N, Mock; &, Con-; and m, Rac1-siRNA) values given represent mean
total cell numbers (+ s.e.m) from 3 independent experiments. B. Trypan blue exclusion, used to assess cell viability, shows that Rac1 knockdown has
no effect on endothelial cell viability in either genotype. Bar graph represents mean percentage of viable cells (+ s.e.m) from 3 independent
experiments. C. Wild-type and b3-null endothelial cell migration in response to VEGF was assessed in scratch wound healing assays. Representative
photomicrographs (20 x magnification) of scratches at 0 hr and after 8 hr of migration after VEGF (25 ng/ml) stimulation. Bar graphs represent the
mean percentage migration relative to 0 hours (+ s.e.m.), from 3 independent experiments, displayed by Mock (white), Con- (grey) and Rac1-siRNA
(black) transfected wild-type and b3-null endothelial cells. Under 2D conditions, Rac1-depletion inhibited VEGF-induced migration of both wild-type
and b3-null endothelial cell cells to baseline levels. D. VEGF-stimulated endothelial cell tube formation was assessed in 2D Matrigel cultures.
Representative phase contrast micrographs (20 x magnification) showing cord structures (arrows) that formed 8 hr after seeding of Con- or Rac1-
siRNA transfected cells on 2D Matrigel. Bar graphs represent mean numbers of branch points per field (+ s.e.m.) from 3 independent experiments.
Rac1-depletion inhibited significantly VEGF-mediated tube formation by both wild-type and b3-null endothelial cells (*P,0.0001). Trypan blue
exclusion assays demonstrated that the percentage of cell death of cells isolated from the cord-formation experiment did not change. Bar graph
represents mean percentage of cell death (+ s.e.m.) from 3 independent experiments. E. In vitro VEGF-mediated endothelial cell migration was
assessed in a modified 3D Boyden chamber assay. Quantification of VEGF-mediated migration of Mock, Con- or Rac1-siRNA transfected wild-type
(left) and b3-null (right) endothelial cells in the presence or the absence of DC101. Bar graphs represent mean percentage migration relative to Mock
treated cells in the absence of VEGF (+ s.d). VEGF-mediated migration was significantly reduced in Con siRNA DC101 treated endothelial cells,
confirming the requirement of Flk-1 in VEGF-induced migration and provides a control (*P,0.05) siRNA targeting of Rac1 did not affect wild-type
(n.s.d), but did inhibit b3-null, endothelial cell migration in 3D conditions (*P,0.01). N=3–5 independent experiments.
doi:10.1371/journal.pone.0009766.g008
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transformation progresses [16]. In addition, vascular b3-integrin
levels were significantly lower in lung metastases from colorectal
carcinomas when compared with those seen in primary
colorectal tumors [17,18]. Thus, targeting b3-integrin might
not be a useful anti-angiogenic strategy for this particular subset
of patients.
One question that remains unanswered is: ‘‘when is b3-integrin
actually bound to ligand during the angiogenic process?’’ Wow-1 is
an antibody that recognizes ligated b3 integrin in cells in culture
[58] but, unfortunately, has yet to be proven to work in whole
tissue sections or in vivo. Thus testing b3-integrin ligation in vivo is
presently impossible without the use of inhibitors. Importantly,
since inhibition of b3-ligation does not phenocopy the deficiency
of b3-integrin, where such angiogenic responses are enhanced
[12], it is also not possible to test whether b3-integrin ligation is
truly relevant to our in vitro findings. This is because inhibition of
b3-ligation, using RGD mimetics or antibodies, can inhibit tubule
formation, for many reasons including an increase in cell death
[59]. Thus inhibiting b3-integrin function not only inhibits b3-
ligation but also simultaneously alters downstream signaling.
Furthermore, we have recently shown that low doses of such
agents can actually enhance angiogenesis, both in vitro and in
vivo, but that these doses do not affect ligand binding [60]. Thus in
conclusion, although such experiments would be of great interest
we await the technology to enable us to test the effect of b3-
ligation effectively in vivo without the use of inhibitors or knockout
mice.
Our findings suggest that inhibition of Rac1 might be an
effective anti-angiogenic therapeutic strategy in tumor blood
vessels that display low levels of b3-integrin. Furthermore,
combination therapy of anti-Rac1 and anti-b3-integrin targeted
to endothelial cells may be an effective general anti-angiogenic
strategy.
Figure 9. Endothelial Rac1-depletion does not affect the expression of Flk-1. A. Western blot analysis of Flk-1 expression levels in primary
wild-type and b3-null endothelial cells transfected with scrambled (Con siRNA) or Rac1 (Rac1 siRNA) siRNAs. Although Flk-1 expression was increased
significantly in b3-null endothelial cells when compared with wild-types (*P,0.01), Rac1-depletion did not affect Flk-1 levels (n.s.d) in either genotype.
Bar graph represents mean (+ s.e.m.) of Flk-1 expression relative to Hsc-70 loading control (N=3–4 independent experiments). B. HUVEC were
transfected with vector only, a wild-type Rac1 construct (Rac1 WT), or a constitutively active Rac1 construct (Rac1 QL) and seeded on confluent
fibroblasts. Tubules were visualized by PECAM1 staining 5 days after seeding. The mean number of branch points (+SEM) is shown in the
accompanying bar chart. (n=12 microscopic fields per condition). Scale bar: 100 mm.
doi:10.1371/journal.pone.0009766.g009
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Ethics Statement
All procedures on mice were performed in accordance with the
United Kingdom Home Office regulations.
Mice
b3-integrin-deficient and wild-type Tie1-Cre mice used for
analysis of pSico lentiviruses in vivo were generated by crossing b3-
integrin-deficient [61] and wild-type mice with Tie1-Cre trans-
genic mice ([62]; kindly provided by Prof. Fa ¨ssler, Max Plank
Institute of Biochemistry, Martinsried, Germany), both on a mixed
C57BL6/129 background. b3-integrin-deficient and wild-type
mice were also bred with the ImmortomouseH (Charles River
Laboratories, MA, USA) on a C57BL6 background and were used
for preparation of immortalised endothelial cell cultures employed
in some of the in vitro assays. Inducible vascular endothelium-
specific Rac1-deficient mice (Rac1 flox/flox PDGFB-iCreER)
were generated by crossing Rac1 flox/flox mice on a mixed
C57BL6/129 background [28] with PDGFB-iCreER transgenic
mice on a mixed C57BL6/CBAF2 background [29].
Isolation of mouse endothelial cells
Mouse lung endothelial cells (MLEC) were isolated as previously
reported [63]. Briefly, minced lungs were digested in collagenase
type 1 (Gibco) and passed trough a 70 mm pore size cell strainer
(BD Falcon) and cell suspension plated onto tissue culture plates
coated with 0.1% gelatin containing 10 mg/ml fibronectin (Sigma)
and 30 mg/ml Purecol (Nutacon). When cells reached ,80%
confluency, macrophages were removed from the culture by
immunosorting using rat anti-mouse CD16/CD32 Fcc receptor
antibodies (AbD Serotech) and with two subsequent sorts using rat
anti-mouse ICAM-2 antibodies (AbD Serotech) endothelial cells
were positively selected. Endothelial cell purity was 96–98% as
assessed by performing flow cytometry for PECAM-1 (clone MEC
13.3, Pharmingen), Endoglin (Pharmingen) and ICAM-2 expres-
sion. Acquisition of samples was performed on a FACS Calibur
fluorescence activated cell sorter (BD Biosciences) and the data
were analysed with CELLQUEST software (BD Biosciences).
Cells were cultured routinely in a 50:50 mix of Hams F12 and D-
MEM media supplemented with 20% FCS, 6 mM glutamine,
25 mg/ml endothelial mitogen (Biogenesis), 1 mg/ml heparin and
antibiotics.
Generation of pSico-Rac1 lentivirus
The plasmid for Stable RNA interference conditional (pSico)
was a kind gift from Dr. Tyler Jacks (Massachusetts Institute of
Technology, MA, USA) [64]. The pSico-Rac1 lentiviral vector
was produced by digesting the pSico construct with HpaI-XhoI
restriction enzymes (Promega), inserting shRNA oligonucleotides
to target the mouse Rac1 gene and religating using T4 DNA ligase
(Promega). A pSico containing shRNA to target the firefly
Luciferase gene (pSico-Con) was generated to serve as a non-
specific control RNAi and a pSico containing shRNA to target the
mouse VEGFR2/Flk-1 gene (pSico-Flk-1) was made to stably
knockdown the expression of Flk-1, therefore serving as a positive
control in angiogenesis assays. Oligonucleotides coding shRNA for
mouse Rac1, mouse VEGFR2/Flk-1, b3-integrin [65] and firefly
Luciferase were designed using the program PSICOLIGO-
MAKER 1.5 (available on Jacks’ website). Luciferase oligos were
blasted against the mouse genome to ensure that they do not
recognise any sequence in the mouse DNA. All oligonucleotide
sequences are available upon request. Chemically competent E.
coli (One Shot Stbl3, Invitrogen) were transformed with ligated
DNA. Plasmids were purified (QIAprep kit, Quiagen), digested
with SacII-NotI (Promega) and positive clones released a fragment
approximately 50 bp larger than the fragment released by pSico
empty vector. Positive clones were sequence verified (Equipment
Park Laboratory, London Research Institute Cancer Research
UK). Sequences were analysed using DNA Strider 1.4f1 software
(CEA, France).
Lentiviruses were generated essentially as described in the
Virapower Lentiviral Expression System User Manual (Invitro-
gen). Briefly, 3 mg of pSico-Rac1, pSico-Con or pSico-Flk-1
lentiviral vectors and 9 mg of ViraPower Packaging Mix (Invitro-
gen) were cotransfected in 293FT cells (Invitrogen) by using
Lipofectamine 2000 reagent (Invitrogen). Supernatants were
collected 48–72 hr after transfection, centrifuged at 3000 rpm
for 15 min, filtered through a 0.45 mm filter, and used to directly
infect primary mouse lung endothelial cells. Overnight infection
usually was sufficient to infect 50–65% of the cells as assessed by
flow cytometry. Acquisition of samples was performed on a FACS
Calibur fluorescence activated cell sorter (BD Biosciences) and the
data were analysed with CELLQUEST software (BD Biosciences).
GFP-positive endothelial cells were sorted 3–4 days after
transfection using a FACSAria cell sorter and program. Sorted
cells were used to assess efficiency of Cre-mediated RNAi in vitro
by transfecting them with Cre expression-plasmid, pTURBO-Cre
(a kind gift from Dr. David Stevenson, The Beatson Institute, UK).
Transfection of cells was performed by electroporation using the
Basic Nucleofector kit designed for primary mammalian endothe-
lial cells (Amaxa GmbH) following the manufacturer’s instructions.
One week after transfection with pTURBO-Cre, Rac1 and Flk-1
knockdown efficiencies were assessed by RT-PCR and Western
blotting. For in vivo experiments, lentivirus were ultracentrifuged
at 25000x g for 1.5 hr and stocks titrated. Titers ranged between
1.5–2610
6 i.u/ml.
Rac1 siRNA
To target mouse Rac1 gene we used siGENOME ON-
TARGETplus SMARTpool reagent (Dharmacon). Primary and
immorto MLEC and mouse aortic tissue (see below) were
transfected with anti-mouse Rac1 siRNA using Oligofectamine
reagent (Invitrogen) following the manufacturer’s instructions. The
final concentration of oligonucleotides in the transfection mixture
was 100 nM and gene expression was examined 48 hr (MLEC) or
5 days (aortic tissue) post-transfection by RT-PCR and Western
Blot analysis. In all transfection experiments scrambled siRNA
(Dharmacon)-transfected samples were used as controls.
Semiquantitative RT-PCR
We used Rac1 isoform-specific primers derived from cDNA
mouse sequences and PCR conditions that have been described
previously [37]. As controls of the Rac2 and Rac3 reactions, total
RNA and subsequent cDNA synthesis from spleen and brain
tissues were obtained. Actin RT-PCR was performed as a loading
control.
Western blot analysis
Cells were grown to ,80% confluency and lysed with RIPA
buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.25% sodium
deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM sodium
orthovanadate, 1 mM NaF, 1 mM PMSF), supplemented with
protease inhibitor cocktail II (Calbiochem). For preparation of
lysates from aortas, 12–15 aortic rings were homogenised in 50 ml
RIPA buffer by using a pestle and microwaved for 10–15 sec.
Homogenates were centrifuged at 10,000 rpm for 10 min at 4uC,
to pellet insoluble material. Lysates were subjected to SDS-PAGE
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ences). Membranes were blocked in either 5% milk or 5% BSA in
PBS-Tween (0.05%) and incubated with mouse anti-Rac1 (Clone
23A8, Upstate), mouse anti-Cdc42 (Chemicon), mouse anti-RhoA
(Santa Cruz) or rabbit anti-VEGFR2 (Cell Signalling Technolo-
gies) antibodies. Membranes were washed three times in PBS-
Tween (0.05%) and subsequently incubated with HRP-conjugated
IgGs. Immunoreactive bands were visualised by incubating the
membranes with ECL chemiluminescence reagents (Amersham
Life Science) and exposing the membranes to autoradiography
film (Amersham Life Science). After detection of the protein of
interest, membranes were stripped with stripping solution
(Chemicon), and re-blotted with mouse anti-Hsc-70 antibody.
Densitometry was performed using a gel acquisition and analysis
set-up (UV Products, Ltd.). Band densities were normalised to
Hsc-70 to make quantitative measurements of the protein of
interest.
Rho GTPases activity assays
A construct encoding glutathione S-transferase (GST) linked to
the amino acid residues 57 to 141 of the PAK-CRIB domain
(GST-PAK-CRIB; kindly provided by Dr. John Collard, King’s
College, London, UK and Dr. Vania Braga, Imperial College,
London, UK), was used to pull down active Rac1 and Cdc42 from
MLEC cell lysates transfected with scrambled or Rac1 siRNA.
Pull-downs were performed as described [66]. Samples of lysate
preincubation (total protein) and postincubation with the GST-
PAK-CRIB beads (active protein) were resolved in 12%
polyacrylamide gels, transferred to PVDF membranes, and
immunoblotted with anti-Rac1 or anti-Cdc42 antibodies as
described above. The proportion of active Rac1 and Cdc42
relative to their the total amount in the cells was determined by
densitometry (UV Products, Ltd.). Active levels of RhoA in MLEC
transfected with scrambled or Rac1 siRNA, were assessed using
the G-LISA
TM RhoA activation assay Biochem Kit
TM (Cystoske-
leton) following the manufacturer’s instructions. The degree of
RhoA activation was determined by comparing absorbance
readings at 490 nm from Rho control protein (constitutively
active RhoA protein) samples versus cell lysates of interest.
In vivo tumorigenesis and endothelial-specific Rac1-
deletion
Rac1 flox/flox and Rac1 flox/flox PDGFB-iCreER mice were
implanted subcutaneously with tamoxifen (Rac1 flox/flox and
Rac1 flox/flox PDGFB-iCreER) or placebo (Rac1 flox/flox
PDGFB-iCreER) 1 mg-slow release pellets in the scruff of the
neck. One day later B16F0 tumor cells (1610
6) were injected
subcutaneously in the flank. At day 10 after tumor cell injections,
tumors were dissected out and processed for histology.
In vivo VEGF-induced angiogenesis assays
Mouse subcutaneous sponge angiogenesis assays [67] were
carried out by implanting two autoclaved sponges subcutaneously
into the flanks of wild-type/Tie1-Cre+ and b3-null/Tie1-Cre+
mice. Sponges were injected in situ as follows: on days 1, 5 and 9
with 100 ml of 10 ng/ml VEGF-A164; on days 3, 7 and 13 with
pSico-Con, pSico-Rac1 and pSico-Flk-1 (10
6 i.u/ml) in 100 mlo f
10 ng/ml VEGF-A164. At day 15 after sponge implantations, the
mice were euthanized by CO2 asphyxiation, sponges excised and
fixed for paraffin embedding. Additionally growth factor induced
angiogenesis assays were carried out by implanting two autoclaved
sponges subcutaneously into the flanks of wild-type and b3-null
mice. These sponges were further injected in situ every 2 days with
Con siRNA (3 mg) in 100 ml of PBS alone, Con siRNA (3 mg) or
Rac1 specific-siRNA (3 mg) in 100 ml of PBS containing 10 ng/ml
VEGF-A164. At day 15 after sponge implantation, the mice were
euthanized by CO2 asphyxiation, sponges excised and processed
for histology.
Quantification of blood vessel density
Tumor and sponge samples were snap frozen for cryosectioning
or fixed in 4% paraformaldehyde for paraffin-embedding,
respectively. Frozen sections were brought to room temperature,
fixed in 4% PFA and rehydrated in PBS, whilst paraffin embedded
sections were deparaffinized, rehydrated in PBS and microwaved
on full power (950 W) in sodium citrate buffer pH 6.0, before
incubation with rat anti-mouse PECAM-1 (Pharmingen), rabbit
anti-green fluorescent protein (GFP) (Mol Probes) and rat anti-
mouse endomucin (kindly provided by Dr. Dietmar Vestweber,
Max-Planck-Institute of Molecular Biomedicine, Muenster, Ger-
many) followed by incubation with goat anti-rat Alexa Fluor-546,
goat anti-rabbit Alexa Fluor-488 (both from Mol Probes) and
biotinylated rabbit anti-rat antibody (Vector Laboratories),
respectively. When biotinylated antibody was used an alkaline
phosphatase-based system (VECTASTAIN ABC-AP, Vector
Laboratories, Peterborough, UK) with Vector Blue substrate kit
(Vector Laboratories, Peterborough, UK) was used to amplify the
signal according to the manufacturer’s instructions. Blood vessel
density in immunofluorescent stained sections from size-matched
tumors was determined by counting the number of PECAM-1
+/
GFP
2 or PECAM-1
+ blood vessels present across an entire section
and then dividing by the total area of the section. Blood vessel
density in immuno alkaline-phosphatase stained sections from
sponges was determined by counting the number of endomucin+/
GFP2 stained blood vessels present across an entire section and
then dividing by the total area of the section. In all cases blood
vessel counting was performed in a double-blind fashion using an
epifluorescence microscope Zeiss (Carl Zeiss, Jena, Germany) with
associated digital camera (Hamamatsu Photonics, Ltd., Welwyn
Garden City, UK) and using Open Lab software v4.1software
(Improvission, Coventry, UK) to capture images and calculate
areas of the sections.
Ex vivo mouse aortic ring assays
Wild-type and b3-integrin-deficient mice were sacrificed by
cervical dislocation, thoracic aortas removed under sterile
conditions, periaortic fibroa d i p o s et i s s u ew a sr e m o v e da n d
aortas were cut into 0.5–1 mm-wide rings. After 24 hours
siRNA transfected aortic rings were rinsed in D-MEM
supplemented with 6 mM L-glutamine and 2% FCS (basal
medium) and each ring was transferred to a well of a 96-well
plate containing polymerized growth factor reduced (GFR)-
Matrigel (Becton Dickson, Beds, UK) before adding 150 mlo f
basal medium. The medium was supplemented with 25 ng/ml
VEGF-A164 and DC101 at 20 mg/ml [27]. Where DC101 was
used, the GFR-Matrigel was supplemented with 20 mg/ml
DC101 antibody just before polymerisation. The cultures were
grown at 37uCa n d8 %C O 2, for up to 8 days. Aortic rings were
examined microscopically and media including VEGF and
DC101 was changed every 2 days. On day 5, phase contrast
photomicrographs were taken using an inverted microscope
( C a r lZ e i s s )e q u i p p e dw i t hac a m e r a( H a m a m a t s uP h o t o n i c s ,
Ltd.) and angiogenesis calculated by counting the number of
capillary sprouts per ring. Rac1 expression in transfected aortic
rings was assessed by using both semiquantitative RT-PCR and
Western blot analysis.
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These assays were performed as described in [68]. The
constructs used are described in [32].
Mouse lung endothelial cell growth
Temperature-sensitive immortalised wild-type and b3-null
mouse lung endothelial cells were plated at density of 1,500 per
square centimetre on pre-coated tissue culture plastic. siRNA
transfections were performed and cells were allowed to continue
growing. Cells were trypsinized from triplicate wells every day for
up to three days and counted using a haemocytometer (Fast Read
102 cell counting chamber [ISL, Paignton, UK]). Cell viability was
assayed by Trypan blue exclusion method.
Wound closure scratch assays
Wound closure scratch assays were performed as described (21).
Briefly, immortalised b3-null and wild-type MLEC were plated at
a density of 10,000 per square centimetre on pre-coated tissue
culture plastic. siRNA transfections were performed and cells were
grown until a confluent monolayer was achieved. Cells were serum
starved for 3 hr, monolayers scratched with a P200 tip, and the
scratches were photographed using an inverted microscope (Carl
Zeiss Axioplan) equipped with a camera (Hamamatsu Photonics,
Ltd.) at three points along their length. The medium was changed
for 50:50 mix DMEM:Hams F12 plus glutamine supplemented
with VEGF-A164 (25 ng/ml) and cells allowed to migrate over
8h ra t3 7 uC. Scratches were rephotographed, and the percentage
of migration was determined relative to the scratch width at 0 hr.
Modified Boyden chamber assays: 3D migration assay
One day before setting up the 3D migration assays, Con- and
Rac1- siRNA transfected b3-null and wild-type and immortalised
MLEC were treated with 4 mg/ml Mitomycin C (Sigma, Dorset,
UK) at 37uC for 2 hr, to avoid changes in cell proliferation. Cells
were washed twice in PBS and serum starved overnight in D-
MEM:Ham’s F12 plus L-glutamine. Matrix solution was prepared
by mixing 1 part of GFR-Matrigel with 1 part of D-MEM:Ham’s
F12 media. 70 ml of matrix solution was pipetted into the upper
well of the transwell (Costar, MA, USA) and incubated at 37uC for
at least 60 min. D-MEM:Ham’s F12 plus L-glutamine and 2.5%
FCS supplemented with growth factor alone or growth factor and
inhibitor (VEGF-A164 [25 ng/ml] and DC101 [50 ng/ml]) were
pipetted into the ‘lower chamber’. Cells resuspended in D-
MEM:Ham’s F12 plus L-glutamine and 2.5% FCS at 50000–
75000 per transwell were seeded onto the ‘top chamber’ and
allowed to migrate at 37uC, 8% CO2 for 72 hr. Analysis of
migrating cells was carried out by counting the number of cells
that passed through the transwell after that period. In each
experiment, each sample/condition was always assessed in
quadruplicate.
Endothelial tube-like cord formation
Wild-type and b3-null immortalised Mock, Con- and Rac1-
siRNA transfected MLEC were starved overnight in 1% FCS in
DMEM:Hams F12 plus glutamine. GFR-Matrigel was diluted 1:1
in DMEM:Hams F12 plus glutamine on ice, mixed or not with
VEGF-A164 at 25 ng/ml final concentration, pipetted onto
10 mm glass coverslips and incubated at 37uC for 30 min. Cells
at 120,000 cells/ml in DMEM:Hams F12 plus glutamine were
plated per well/coverslip and incubated at 37uC. Every two hours
cells were observed under an inverted microscope (Carl Zeiss
Axioplan) equipped with a camera (Hamamatsu Photonics, Ltd.),
and photographed. Branch points of developing tubular structures
were counted and compared at 8 hr time-point.
Analysis of Statistical Significance
Data sets were analysed for significance using Student’s t test.
P,0.05 was considered statistically significant. Experiments were
carried out in a double blind fashion and all experiments were
performed in triplicate.
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